Rap_GAP Domain of TSC2 Contributes to Tumor Suppression Through mTOR Signaling in Human Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is a highly heterogeneous and aggressive cancer.
• Genetic alterations in mTOR-related genes and mTOR pathway hyperactivation are frequently observed in HCC.
• The precise role of genetic alterations in hepatocarcinogenesis remains incompletely understood.

Purpose of the Study:

• To investigate the causal link between TSC2 truncating mutations and mTOR pathway hyperactivation in HCC.
• To determine if TSC2 genetic alterations contribute to the development of hepatocellular carcinoma.
• To explore therapeutic implications of targeting the mTOR pathway in HCC.

Main Methods:

• Generation of HCC cell models with TSC2 deletion (CRISPR/Cas9) and TSC2 truncating mutations (mutagenesis).
• Analysis of mTOR signaling pathway activity in engineered HCC cell lines.
• Immunohistochemical analysis of TSC2 expression in clinical HCC samples.

Main Results:

• Both TSC2 deletion and TSC2 truncating mutations resulted in TSC2 loss-of-function.
• Loss of TSC2 function led to significant hyperactivation of the mTOR signaling pathway.
• Rapamycin treatment effectively reversed the hyperactivation of mTOR signaling.
• Clinical HCC samples frequently exhibited TSC2 loss.

Conclusions:

• Genetic alterations, particularly truncating mutations in TSC2, cause loss of function, leading to mTOR pathway hyperactivation in HCC.
• The high frequency of TSC2 truncating mutations near the Rap_GAP domain is a significant factor contributing to mTOR hyperactivation in HCC patients.
• These findings highlight TSC2 as a critical player in hepatocarcinogenesis and suggest potential therapeutic strategies targeting the mTOR pathway.